Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Sato, Shinji ^a   Murakami, Akihiro ^b   Kuwajima, Akiko ^b   Takehara, Kazuhiko ^c   Mimori, Tsuneyo ^d   Kawakami, Atsushi ^e   Mishima, Michiaki ^d   Suda, Takafumi ^f   Seishima, Mariko ^g   Fujimoto, Manabu ^h   Kuwana, Masataka ⁱ  

^a TOKAI UNIVERSITY   (Japan)

^b Medical & Biological Laboratories Co Ltd   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g GIFU UNIVERSITY   (Japan)

^h UNIVERSITY OF TSUKUBA   (Japan)

ⁱ NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 AUTOANTIBODY; UNCLASSIFIED DRUG; IFIH1 PROTEIN, HUMAN; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1;

ADULT; ANTIBODY DETECTION; ARTHRITIS; ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; IMMUNOPRECIPITATION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; POLYMYOSITIS; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; UNIVERSITY HOSPITAL; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASES; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; GENETICS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; STANDARDS;

ADULT; AGED; AUTOANTIBODIES; CASE-CONTROL STUDIES; CONNECTIVE TISSUE DISEASES; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IMMUNOPRECIPITATION; INTERFERON-INDUCED HELICASE, IFIH1; MALE; MIDDLE AGED; POLYMYOSITIS; SENSITIVITY AND SPECIFICITY;

EID: 84977544748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154285     Document Type: Article

References (29)

1. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007; 19: 523-529. PMID: 17917530
2. Sato S, Kuwana M. Utility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting. Int J Clin Rheumatol. 2015; 10: 257-271.
3. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005; 52: 1571-1576. PMID: 15880816
4. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009; 60: 2193-2200. doi: 10.1002/art.24621 PMID: 19565506
5. Fujikawa K, Kawakami A, Kaji K, Fujimoto M, Kawashiri S, Iwamoto N, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol. 2009; 38: 263-267. doi: 10.1080/ 03009740802687455 PMID: 19444719
6. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010; 49: 1726-1733.
7. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011; 147: 391-398. doi: 10.1001/archdermatol.2011.52 PMID: 21482889
8. Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiationassociated gene 5 antibody. Arthritis Care Res (Hoboken). 2012; 64: 1602-1610.
9. Chaisson NF, Paik J, Orbai AM, Casciola-Rosen L, Fiorentino D, Danoff S, et al. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore). 2012; 91: 220-228.
10. Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiationassociated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken). 2013; 65: 1316-1324.
11. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res. 2014; 2014: 290797. doi: 10.1155/2014/290797 PMID: 24741583
12. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292: 344-347. PMID: 1090839
13. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002; 46: 626-636. PMID: 11907524
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62: 2569-2581. doi: 10.1002/art.27584 PMID: 20872595
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271-1277. PMID: 7138600
16. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980; 23: 581-590. PMID: 7378088
17. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61: 554-558. PMID: 12006334
18. Porter JF, Kingsland LC 3rd, Lindberg DA, Shah I, Benge JM, Hazelwood SE, et al. The AI/RHEUM knowledge-based computer consultant system in rheumatology. Performance in the diagnosis of 59 connective tissue disease patients from Japan. Arthritis Rheum. 1988; 31: 219-226. PMID: 3279963
19. Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011: 105: 1238-1247. doi: 10.1016/j.rmed.2011.03.022 PMID: 21514811
20. Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med. 2008; 205: 1601-1610. doi: 10.1084/jem.20080091 PMID: 18591409
21. Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, et al. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One. 2014; 9: e85062. doi: 10.1371/journal.pone.0085062 PMID: 24454792
22. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010; 49: 433-440.
23. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011; 105: 1380-1387. doi: 10.1016/j.rmed.2011.05.006 PMID: 21632230
24. Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-MDA5-associated dermatomyositis: Expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013; 65: 1307-1315.
25. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011; 65: 25-34. doi: 10.1016/j.jaad.2010.09.016 PMID: 21531040
26. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of antimelanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012; 51: 1278-1284.
27. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C, et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol. 2014; 32: 891-897. PMID: 25151986
28. Sato S, Kuwana M, Fujita T, Suzuki Y. Amyopathic dermatomyositis developing Rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol. 2012; 22: 625-629. doi: 10.1007/s10165-011-0558-9 PMID: 22124544
29. Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013; 23: 496-502. doi: 10.1007/s10165-012-0663-4 PMID: 22644102